Carcinoma News and Research

RSS

Carcinoma is cancer that begins in the skin or in tissues that line or cover internal organs.

Positive interim data from cabozantinib Phase 2 metastatic castration-resistant prostate cancer trial

Exelixis, Inc. today reported updated interim data from the cohort of patients with metastatic castration-resistant prostate cancer (CRPC) treated with cabozantinib (XL184) in an ongoing phase 2 adaptive randomized discontinuation trial.

18 Feb 2011

Urocidin Phase III non-muscle-invasive bladder cancer trial interim results to be presented at EAU, AUA conferences

Endo Pharmaceuticals and Bioniche Life Sciences Inc. today announced plans for peer-reviewed presentation of interim efficacy and safety results from the first Phase III trial of the intravesical formulation of Mycobacterial cell wall-DNA complex (MCC), known as Urocidin™ or EN3348.

18 Feb 2011

Apricus Bio in discussions with FDA for PrevOnco SPA Phase III protocol

Apricus Biosciences, Inc., announced today that it is currently in discussions with the U.S. Food and Drug Administration ("FDA") relating to the PrevOnco™ Special Protocol Assessment ("SPA") Phase III protocol submitted by the Company in December 2010.

18 Feb 2011

Two researchers receive Brupbacher Prize for Cancer Research 2011

Today, the Charles Rodolphe Brupbacher Prize for Cancer Research 2011 goes to two researchers who have contributed to better understanding of the genetics underlying the growth of tumors.

17 Feb 2011

Continued smoking during radiation treatment for head and neck cancer affects prognosis

Smokers who continue to smoke while undergoing radiation treatments for head and neck cancer fare significantly worse than those who quit smoking before therapy, according to a study in the February issue of the International Journal of Radiation Oncology•Biology•Physics, an official journal of the American Society for Radiation Oncology (ASTRO).

17 Feb 2011

Astellas, AVEO enter development, commercialization agreement for tivozanib

Astellas Pharma Inc., a global pharmaceutical company, and AVEO Pharmaceuticals, Inc. today announced that they have entered into a worldwide agreement outside of Asia to develop and commercialize tivozanib, AVEO's lead product candidate designed to optimally block the VEGF pathway by inhibiting all three VEGF receptors, for the treatment of a broad range of cancers.

17 Feb 2011

Smoking during radiation treatments reduces chance of overall survival

Smokers who continue to smoke while undergoing radiation treatments for head and neck cancer fare significantly worse than those who quit smoking before therapy, according to a study in the February issue of the International Journal of Radiation Oncology·Biology·Physics, an official journal of the American Society for Radiation Oncology (ASTRO).

16 Feb 2011

Scientists to present research on RMI ability to classify lung, kidney tumors at USCAP meeting

Clinical researchers from Cornell Weil Medical School and University of Chicago Medical School will present research conducted on Raman Molecular Imaging's ability to differentiate diagnostic dilemmas in lung and kidney tumors at the United States and Canadian Academy of Pathology's 100th Annual Meeting, Feb. 26-March 4 at the Henry B. Gonzalez Convention Center, San Antonio, Texas.

16 Feb 2011

Study: Active wound healing can lead to increased risk of basal cell carcinoma in skin

Processes that are involved in active wound healing can lead to an increased risk for basal cell carcinoma in the skin. This is the conclusion of a recent study from the Swedish medical university Karolinska Institutet, published in the journal PNAS.

15 Feb 2011

Neoprobe achieves accrual goal in Lymphoseek Phase 3 study in breast cancer/melanoma

Neoprobe Corporation, a diversified developer of innovative oncology surgical and diagnostic products, today announced that a multi-center Phase 3 study of Lymphoseek® has enrolled clinical subjects to achieve the minimum analysis goal of 196 lymph nodes, the study's primary accrual objective.

14 Feb 2011

Positive clinical data of AVEO's tivozanib featured at 2011 ASCO Genitourinary Cancers Symposium

AVEO Pharmaceuticals, Inc. today announced that previously reported positive clinical data evaluating tivozanib, its lead product candidate designed to optimally block the VEGF pathway by inhibiting all three VEGF receptors, in patients with renal cell carcinoma (RCC) will be featured in several poster presentations at the American Society of Clinical Oncology (ASCO) 2011 Genitourinary Cancers Symposium being held February 17-19, 2011 at the Orlando World Center Marriott in Orlando, Fla.

14 Feb 2011

Two Uofl professors provide reference works in oncology field

Two University of Louisville School of Medicine professors recently authored reference works in the field of oncology, one focusing on the use of radiation treatment for childhood cancers and the other on hepatocellular carcinoma, or liver cancer.

14 Feb 2011

Afinitor plus BSC doubles progression-free survival in patients with advanced pancreatic neuroendocrine tumors

The New England Journal of Medicine (NEJM) published a study today that shows Afinitor® (everolimus) tablets plus best supportive care (BSC) more than doubled progression-free survival (PFS), or time without tumor growth, versus placebo plus BSC in patients with advanced pancreatic neuroendocrine tumors (NET).

10 Feb 2011

Everolimus phase III study shows improved progression-free survival in patients with pNET

In an international Phase III randomized study, everolimus, an inhibitor of the mammalian target of rapamycin, has shown to dramatically improve progression-free survival for patients with advanced pancreatic neuroendocrine tumors, according to researchers from The University of Texas MD Anderson Cancer Center.

9 Feb 2011

Aushon BioSystems enters diagnostic development collaboration with Peking University Cancer Hospital

Aushon BioSystems, Inc., a leading provider of multiplex immunoassay products and services announced that it has signed a letter of intent to enter into a diagnostic development collaboration with Peking University Cancer Hospital ("PUCH"), Beijing, China.

9 Feb 2011

Genentech's OCEANS Phase III study of Avastin in platinum-sensitive ovarian cancer meets primary endpoint

Genentech, a member of the Roche Group, announced today that OCEANS, a Phase III study evaluating Avastin® (bevacizumab) in combination with chemotherapy (carboplatin and gemcitabine) followed by continued use of Avastin alone until disease progression in women with previously treated (recurrent), platinum-sensitive ovarian cancer, met its primary endpoint.

8 Feb 2011

Research unmasks long sought stem cell origin of carcinoma

A constellation of different stem cell populations within our skin help it to cope with normal wear and tear. By constantly proliferating, the stem cells allow skin to replenish itself, allowing each cell to be replaced by a new one about once a month. But the normal cycle of division and death within one or more of these stem cell types can sometimes be derailed by genetic mishaps. Such events are believed to spawn carcinomas and other deadly skin cancers, which are the mostly frequently diagnosed cancers in the United States.

4 Feb 2011

AVEO receives USAN, WHO generic name approval for ficlatuzumab

AVEO Pharmaceuticals, Inc. today announced that the United States Adopted Names (USAN) Council, in consultation with the World Health Organization (WHO) International Nonproprietary Names Expert Committee, has approved the use of the nonproprietary generic name "ficlatuzumab" (pronounced fye" kla tue' zue mab) for AV-299, a potent, functional anti-HGF/c-MET antibody internally discovered at AVEO.

3 Feb 2011

Merck announces publication of GARDASIL pivotal Phase III study data in NEJM

Merck announced today that data from the pivotal Phase III study with GARDASIL in males were published in the February 3 issue of the New England Journal of Medicine.

3 Feb 2011

AVEO commences enrollment in tivozanib Phase 2 study in renal cell carcinoma

AVEO Pharmaceuticals, Inc. today announced that it has initiated patient enrollment in a multi-center Phase 2 exploratory biomarker study of tivozanib, its lead product candidate designed to optimally block the VEGF pathway by inhibiting all three VEGF receptors, in patients with renal cell carcinoma (RCC).

1 Feb 2011

Carcinoma News and Research

Further Reading

Positive interim data from cabozantinib Phase 2 metastatic castration-resistant prostate cancer trial

Urocidin Phase III non-muscle-invasive bladder cancer trial interim results to be presented at EAU, AUA conferences

Apricus Bio in discussions with FDA for PrevOnco SPA Phase III protocol

Two researchers receive Brupbacher Prize for Cancer Research 2011

Continued smoking during radiation treatment for head and neck cancer affects prognosis

Astellas, AVEO enter development, commercialization agreement for tivozanib

Smoking during radiation treatments reduces chance of overall survival

Scientists to present research on RMI ability to classify lung, kidney tumors at USCAP meeting

Study: Active wound healing can lead to increased risk of basal cell carcinoma in skin

Neoprobe achieves accrual goal in Lymphoseek Phase 3 study in breast cancer/melanoma

Positive clinical data of AVEO's tivozanib featured at 2011 ASCO Genitourinary Cancers Symposium

Two Uofl professors provide reference works in oncology field

Afinitor plus BSC doubles progression-free survival in patients with advanced pancreatic neuroendocrine tumors

Everolimus phase III study shows improved progression-free survival in patients with pNET

Aushon BioSystems enters diagnostic development collaboration with Peking University Cancer Hospital

Genentech's OCEANS Phase III study of Avastin in platinum-sensitive ovarian cancer meets primary endpoint

Research unmasks long sought stem cell origin of carcinoma

AVEO receives USAN, WHO generic name approval for ficlatuzumab

Merck announces publication of GARDASIL pivotal Phase III study data in NEJM

AVEO commences enrollment in tivozanib Phase 2 study in renal cell carcinoma

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News